Vps34 strengthens the immuno-oncology field
Previous research has shown that tumors use autophagy to escape the body's immune system. Sprint Bioscience has shown that inhibition of autophagy with the company's substance SB02024 activates the immune system in the tumor.
With the new information, Sprint Bioscience is now presenting the Vps34 project as an immuno-oncology project. Immuno-oncology is a new field in cancer drug treatment, where the patient's own immune cells fights the tumor.
Sprint Bioscience participates in the BIO-Europe Partner Conference in Berlin 6-8 November. During the planned meetings with representatives from the international pharmaceutical industry, the company will present the Vps34 program as an immuno-oncology project. "We know from our contacts with the pharmaceutical industry that immuno-oncology is an area where demand for new projects is high", says Anne-Marie Wenthzel, Head of Business Development at Sprint Bioscience. In addition to the Vps34 program, the company's type 2 diabetes/NASH program, STK25, will also be presented during the conference in Berlin.
About the Vps34 project: Sprint Bioscience has developed selective and potent Vps34 inhibitors with excellent oral bioavailability. The substance SB02024 has been chosen for toxicology studies, prior to the selection of a clinical candidate. Sprint Bioscience has submitted 6 patent applications to the European Patent Office (EPO) to protect SB02024 and other substances.
About Sprint Bioscience:
Sprint Bioscience AB (publ) is part of the new Swedish pharmaceutical industry and has the goal to develop drug candidates for the global pharmaceutical market within the field of oncology in a more time- and resource-efficient manner. Sprint Bioscience is situated in Stockholm, Sweden. Sprint Bioscience share is listed on NASDAQ First North Premier and traded under the name SPRINT.
Additional information is available on the company website; www.sprintbioscience.com.
Certified Advisor is Redeye, www.redeye.se.
For further information, please contact:
Anders Åberg, CEO, Sprint Bioscience
Tel: 46-8-411 44 55
E-mail: anders.aberg@sprintbioscience.com
Sprint Bioscience AB is obliged to make this information public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of the contact persons set out above,
at 08.30 CET on 27 October 2017.
About Sprint Bioscience
Sprint Bioscience AB (publ) is part of the new Swedish pharmaceutical industry and has the goal to develop drug candidates for the global pharmaceutical market within the field of oncology in a more time- and resource-efficient manner. Sprint Bioscience is situated in Stockholm, Sweden. Sprint Bioscience share is listed on Nasdaq First North Premier and traded under the name SPRINT.
Additional information is available on the company website; www.sprintbioscience.com.
Certified Advisor is Redeye, www.redeye.se.
Sprint Bioscience │ Novum│141 57 Huddinge │ Sweden │ 46-(0)8-411 44 55 │info@sprintbioscience.com
Tags:
